세계의 개 아토피 피부염 시장 - 산업 규모, 점유율, 동향, 기회, 예측, 제품별, 투여 방법별, 유통 채널별, 지역별, 경쟁별(2020-2030년)

The global Canine Atopic Dermatitis Market was valued at USD 995.60 million in 2024 and is projected to experience robust growth, with a compound annual growth rate (CAGR) of 9.90% from 2024 to 2030. This market encompasses products and services related to the diagnosis, treatment, and management of atopic dermatitis in dogs-a common skin condition that causes itching, inflammation, and discomfort. The market includes various therapies and treatments aimed at alleviating symptoms and improving the quality of life for affected dogs. According to recent data from the Pet Food Manufacturers' Association (PFMA), the United Kingdom was expected to have 34.9 million pets in 2022, including 13 million dogs. This rising pet population underscores the increasing demand for advanced veterinary care, which has driven the specialization of veterinary professionals in dermatological conditions, highlighting the growing focus on comprehensive pet healthcare services.

Key Market Drivers:

Rising Pet Ownership and Humanization: The global pet industry has seen significant growth, largely due to an increasing number of pet owners worldwide. Along with this trend, pets are increasingly being regarded as family members rather than just companions, a shift that has major implications for various pet-related markets, including the canine atopic dermatitis market. The 2021-2022 American Pet Products Association (APPA) National Pet Owners Survey revealed that dog owners spent an average of USD 458 on surgical veterinary visits and USD 242 on routine visits. This growing investment in pet health, combined with increasing awareness of canine health issues, is driving demand for advanced treatments, including those for conditions such as canine allergic dermatitis, thereby fostering growth in the veterinary care market. In particular, the rise in pet ownership has led to increased demand for healthcare products and services, including treatments for chronic conditions like atopic dermatitis. As pets are increasingly seen as family members, pet owners are more likely to prioritize high-quality healthcare, including preventive measures and ongoing management of conditions such as canine atopic dermatitis.

Key Market Challenges:

Misdiagnosis and Underdiagnosis: A key challenge in managing canine atopic dermatitis is the potential for misdiagnosis or underdiagnosis. Symptoms such as itching, redness, and skin irritation often overlap with other skin conditions, making accurate diagnosis essential. Failing to identify atopic dermatitis can result in improper treatments or a lack of intervention, potentially worsening the dog's condition.

Varied Triggers: Canine atopic dermatitis has various triggers, including environmental allergens, food sensitivities, and genetic factors. Identifying the specific trigger for each dog can be challenging, which makes developing a universal treatment plan difficult. This variability requires a personalized approach to treatment and care.

Compliance and Duration of Treatment: Ensuring compliance with prescribed treatment regimens over the long term can be a challenge for both pet owners and veterinarians. The ongoing nature of the condition necessitates sustained management, which may impact adherence to prescribed therapies.

Key Market Trends:

Advancements in Immunotherapy: Allergen-specific immunotherapy (ASIT) is becoming more refined and accessible. The development of more accurate allergy testing methods and innovative ASIT treatments is expected to enhance the management of atopic dermatitis by targeting the specific allergens that cause the condition in each dog.

Targeted Therapies: Pharmaceutical advancements are leading to the development of targeted therapies that address the underlying causes of canine atopic dermatitis. These treatments aim to reduce the need for long-term symptom management, ultimately improving the quality of life for affected dogs.

Holistic and Alternative Therapies: Holistic and alternative treatments, such as acupuncture, herbal remedies, and physical rehabilitation, are gaining popularity as complementary options for managing atopic dermatitis. These approaches are being recognized for their potential to improve overall well-being and provide additional management options for pet owners seeking non-traditional therapies.

Key Market Players:

• Zoetis Inc.
• Elanco Animal Health Inc.
• Virbac SA
• Toray Industries Inc.
• AB Science SA
• Boehringer Ingelheim GmbH
• Kindred Biosciences Inc.

Report Scope:

This report segments the global Canine Atopic Dermatitis Market into multiple categories, providing valuable insights into industry trends and forecasts. The market is segmented as follows:

By Product:

• Glucocorticoids
• Antihistamines
• Immunosuppressants
• Monoclonal Antibodies (MAbs)
• Others

By Mode of Administration:

• Topical
• Oral
• Injectable

By Distribution Channel:

• Veterinary Hospitals/Clinics
• Retail
• E-commerce

By Region:

• North America: United States, Canada, Mexico
• Europe: Germany, United Kingdom, France, Italy, Spain
• Asia-Pacific: China, Japan, India, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE, Kuwait

Competitive Landscape:

This section offers a detailed analysis of the major players operating in the global Canine Atopic Dermatitis Market.

Available Customizations:

TechSci Research provides customization options for this market report based on specific company requirements. Customization options include detailed profiles of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Canine Atopic Dermatitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 5.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 5.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Product
  • 5.3.2. By Mode of Administration
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Canine Atopic Dermatitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 6.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 6.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Canine Atopic Dermatitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Mode of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Canine Atopic Dermatitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Mode of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Canine Atopic Dermatitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Mode of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Canine Atopic Dermatitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 7.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 7.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Canine Atopic Dermatitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Mode of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Canine Atopic Dermatitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Mode of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. France Canine Atopic Dermatitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Mode of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Canine Atopic Dermatitis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Mode of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Canine Atopic Dermatitis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Mode of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Canine Atopic Dermatitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 8.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 8.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Canine Atopic Dermatitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Mode of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Japan Canine Atopic Dermatitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Mode of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. India Canine Atopic Dermatitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Mode of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Australia Canine Atopic Dermatitis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Mode of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. South Korea Canine Atopic Dermatitis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Mode of Administration
      • 8.3.5.2.3. By Distribution Channel

9. South America Canine Atopic Dermatitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 9.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 9.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Canine Atopic Dermatitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Mode of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Canine Atopic Dermatitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Mode of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Canine Atopic Dermatitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Mode of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Canine Atopic Dermatitis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product (Glucocorticoids, Antihistamines, Immunosuppressants, MAbs, Others)
  • 10.2.2. By Mode of Administration (Topical, Oral, Injectable)
  • 10.2.3. By Distribution Channel (Veterinary Hospitals/Clinics, Retail, E-commerce)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Canine Atopic Dermatitis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Mode of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Canine Atopic Dermatitis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Mode of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Canine Atopic Dermatitis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Mode of Administration
      • 10.3.3.2.3. By Distribution Channel
  • 10.3.4. Kuwait Canine Atopic Dermatitis Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Mode of Administration
      • 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Zoetis Inc
• 14.2. Elanco Animal Health Inc
• 14.3. Virbac SA
• 14.4. Toray Industries Inc
• 14.5. AB Science SA
• 14.6. Boehringer Ingelheim GmbH
• 14.7. Kindred Biosciences Inc

15. Strategic Recommendations

16. About Us & Disclaimer